Studies Confirm HPV Shot Is Safe
New studies included millions of doses of Gardasil 9 vaccine, the only vaccine currently used in the United States for the prevention of HPV-related cancers.
This is a public health success story. A landmark report on the effectiveness of the quadrivalent human papillomavirus vaccine (4vHP) in the U.S. is now a matter of medical record. Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the U.S., with nearly 80 million people infected with some type of HPV at some point in their lives . About 14 million Americans, including teens, become infected each year . HPV causes genital warts and is associated with an estimated 33,700 newly diagnosed cancers every year in the U.S.
CONCLUSIONS: Introducing a two-dose bi-valent HPV vaccination program is cost-effective in Bangladesh at Gavi negotiated prices. Vaccine price is the dominating parameter for the cost-effectiveness of bivalent and quadrivalent vaccines. Both vaccines are not cost-effective at listed prices in Bangladesh. The evaluation highlights that introducing the two-dose bivalent HPV vaccine at Gavi negotiated prices into a national immunization program in Bangladesh is economically viable to reduce the burden of cervical cancer. PMID: 31668820 [PubMed - as supplied by publisher]
OBJECTIVE: To evaluate the knowledge and acceptability of the human papillomavirus (HPV) vaccine among health professionals from western Amazonia. METHODS: A cross-sectional study was conducted in the Sistema Assistencial è Saúde da Mulher e da Criança (Health Care System for Women and Children; SASMC) in Acre, Brazil, in 2017. The participants comprised 196 health professionals. The data collection instrument contained 31 questions about HPV, its clinical repercussions for women, and the HPV vaccine. Quantitative variables were presented as medians and 95% confidence intervals (CIs), and p
Publication date: December 2019Source: Current Opinion in Virology, Volume 39Author(s): Silvia de Sanjose, Maria Brotons, D Scott LaMontagne, Laia BruniSince 2006, 115 countries and territories have introduced human papillomavirus (HPV) vaccination programs.Several efforts have been undertaken to evaluate the impact of HPV vaccines. Many countries, mainly high-income and with high screening coverage, are already reporting a visible impact of the HPV vaccine on HPV-related diseases. Others, largely low-income and middle-income countries, are introducing HPV vaccine to control HPV diseases that will undoubtedly generate a si...
CONCLUSION: Due to the low levels of knowledge about HPVinfection and its methods of prevention, efforts should be increased to enhance the knowledge of the general populationabout HPV infection and vaccination in order to prevent its incidence and complications. PMID: 31350949 [PubMed - in process]
An analysis covering 66 million young people has found plummeting rates of precancerous lesions and genital warts after vaccination against the human papillomavirus.
By Jacqueline Howard, CNN (CNN) — The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, known as ACIP, voted unanimously on Wednesday to recommend HPV vaccines for both boys and girls and men and women through age 26. Previously the CDC recommended that teen girls and young women who had not been adequately vaccinated receive the human papillomavirus vaccine through age 26, but the recommendation for teen boys and young men only went through age 21. The CDC’s recommendation that children start receiving two doses of the HPV vaccine around 11 or 12...
There is a vaccine that can prevent persistent infection with the human papillomavirus (HPV), the etiological agent in many HPV-related cancers worldwide and within the United States. Globally, approximately 570,000 females and 60,000 males are diagnosed annually with a cancer that is related to the HPV.1 More than 90% of all cases of cervical and anal cancers are caused by persistent infection with the HPV, and it causes 75% of all cases of vaginal cancer, 70% of all cases of oropharyngeal and vulvar cancer, and 60% of penile cancer.
In Zambia, cervical cancer screening was started in 2006 and the human papillomavirus vaccine was piloted in 2013. Nevertheless, cervical cancer remains the leading cancer. It is assumed that knowledge, social...
Conditions: Condylomata Acuminata; Cervical Cancer Interventions: Biological: HPV Vaccine,270μg/1.0ml; Biological: Placebo Sponsors: Xiamen University; Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Not yet recruiting